Valeria Pecce

Rome, 00161, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Journal: Atherosclerosis
Published: December 27, 2025

The hidden burden of kidney damage in chylomicronemia syndromes.

The hidden burden of kidney damage in chylomicronemia syndromes.

Journal: Atherosclerosis
Published: September 09, 2025

The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.

The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.

Journal: Molecular oncology
Published: April 02, 2025

Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer.

Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer.

Journal: Endocrine
Published: June 11, 2024

Protocol for oil red O staining of low-density lipoproteins for in vivo cell treatment.

Protocol for oil red O staining of low-density lipoproteins for in vivo cell treatment.

Journal: STAR protocols
Published: May 14, 2024

Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.

Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.

Journal: Journal of endocrinological investigation
Published: April 16, 2024

Effective TRIAC treatment of a THRβ-mutated patient with thyroid hormone resistance.

Effective TRIAC treatment of a THRβ-mutated patient with thyroid hormone resistance.

Journal: Endocrine
Published: February 05, 2024

Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients.

Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients.

Journal: Journal of endocrinological investigation
Published: August 10, 2023

Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance.

Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 29, 2023

Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients.

Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients.

Journal: Journal of endocrinological investigation
Published: March 18, 2023

The role of miR-139-5p in radioiodine-resistant thyroid cancer.

The role of miR-139-5p in radioiodine-resistant thyroid cancer.

Journal: Journal of endocrinological investigation
Published: January 16, 2023

Expression of miR-31-5p affects growth, migration and invasiveness of papillary thyroid cancer cells.

Expression of miR-31-5p affects growth, migration and invasiveness of papillary thyroid cancer cells.

Journal: Endocrine
Published: November 02, 2022
Showing 1-12 of 53

Last Updated: 09/26/2026